Blood Function: 5-ALA + Iron for Cellular Energy

What 5-ALA and iron citrate are

5-aminolevulinic acid is a small, naturally occurring amino acid found in plants, animals, and the human body. We make it ourselves inside our mitochondria, where it serves as the first committed building block in the production of heme. Heme is the iron-rich pigment that gives blood its color, carries oxygen in hemoglobin, and sits at the center of several enzymes the body cannot run without.

Sodium ferrous citrate is a gentle, well-absorbed form of iron. The reason it is combined with 5-ALA comes down to chemistry. Heme is assembled in two parts: a ring-shaped molecule called a porphyrin and a single atom of iron slotted into its center. 5-ALA supplies the raw material for the ring, and the iron citrate supplies the metal that completes it. Giving both at once means the heme pathway is supported from start to finish rather than stalling for want of one ingredient.

How the heme pathway works

Once 5-ALA enters the heme pathway, the body converts it step by step into protoporphyrin IX, and then an enzyme inserts iron to form finished heme. This sequence runs partly in the mitochondria and partly in the surrounding cell, which is why heme production is so closely tied to mitochondrial health.

The finished heme has two jobs that matter for everyday function. In the bone marrow it is loaded into hemoglobin, the protein that lets red blood cells pick up oxygen in the lungs and deliver it throughout the body. Inside mitochondria it becomes part of cytochrome c oxidase, the final enzyme of the electron transport chain. That enzyme is where oxygen is consumed to drive the production of ATP, the energy currency every cell spends. A 2024 review in iScience traced how 5-ALA influences this machinery, describing its effects on cytochrome c oxidase, on the master regulator PGC-1-alpha that controls how many mitochondria a cell builds, and on the Nrf2 and heme oxygenase-1 antioxidant system that protects cells from oxidative stress.

The mitochondrial dysfunction rationale

Mitochondria are the power plants of the cell, and when they falter the effects show up as fatigue, poor exercise tolerance, and trouble recovering. Because 5-ALA feeds both the oxygen-carrying side of metabolism (hemoglobin) and the energy-producing side (the electron transport chain), researchers have studied it as a way to support cells whose mitochondria are under strain.

Animal work backs up that logic. A 2023 study in Obesity tested sodium ferrous citrate with 5-ALA in mice on a high-fat diet and found the combination preserved mitochondrial structure in skeletal muscle, maintained mitochondrial DNA, and protected muscle mass and strength while reducing insulin resistance. The authors concluded the benefit ran specifically through better skeletal muscle and mitochondrial health, which is the clearest preclinical illustration of why the pairing is built the way it is.

The long-COVID connection

Much of the recent attention on this combination grew out of the pandemic. COVID-19 and the lingering symptoms that follow it have been linked to disrupted mitochondrial energy production, and that overlap made a heme-supporting, mitochondria-supporting supplement an obvious candidate to study. A 2022 review in Expert Review of Anti-Infective Therapy laid out the rationale: 5-ALA is converted to protoporphyrin IX and then heme, and it induces heme oxygenase-1, an anti-inflammatory and protective enzyme whose levels are reduced in severe COVID-19. The authors noted that oral 5-ALA with sodium ferrous citrate raised heme oxygenase-1 in the blood of healthy volunteers and called for randomized trials.

Those trials began to arrive. A 2023 randomized exploratory Phase II trial published in Medicine gave 5-ALA phosphate with iron to patients with mild-to-moderate COVID-19. The combination was generally well tolerated, and while it did not change viral load, the treatment group recovered faster from symptoms including taste disturbance, cough, lethargy, and appetite loss. The work is early and the energy-and-recovery questions that motivate long-COVID interest are still open, but it moved the idea from hypothesis into controlled human testing.

What the human research shows

The strongest human data so far come from metabolism. A large double-blind, randomized, placebo-controlled trial in Nutrition enrolled 212 adults with mildly elevated blood sugar and gave them 5-ALA phosphate plus iron as sodium ferrous citrate for twelve weeks. The highest dose lowered fasting glucose, two-hour glucose tolerance, and glycoalbumin compared with placebo, with only minor side effects. The iScience review summarized the broader picture: randomized trials have confirmed 5-ALA's effect on glucose control in prediabetic and diabetic adults, including safe use alongside standard oral diabetes medications.

The combination is now being tested in more demanding settings. A Phase 2 dose-finding trial at the University of Oxford (NCT07027670, 48 participants, completed) gave 5-ALA with sodium ferrous citrate to patients before cardiac surgery on cardiopulmonary bypass, aiming to activate heme oxygenase and protect tissue through a procedure that places real stress on cells. That this heme-and-iron pairing is being studied for cardioprotection in a controlled surgical trial speaks to how seriously its mitochondrial rationale is being taken.

Taken together, the picture is consistent: a naturally occurring building block of heme, paired with the iron that completes it, with encouraging metabolic data in people and active trials extending the work into mitochondrial protection. Whether it fits any individual situation is a question to explore with a qualified clinician after a full assessment.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. 5-ALA with iron is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.